Southern Network News (Reporter/Tang Wenshi) On April 9, the fifth Cloud Cheng Tian Yu Food and Drug Review Certification Technology Summit Forum and the third meeting of the second member representative conference, themed "Building Together, Governing Together, Sharing Together, and Working Together for High Quality," was held at the Guangzhou Huangpu Science City Conference Center. This conference was guided by the Guangdong Provincial Drug Administration, the People's Government of Huangpu District, Guangzhou, and the Development Zone Management Committee, supported by the Huangpu District Market Supervision Administration of Guangzhou, and hosted by the Guangdong Provincial Food and Drug Review Certification Technology Association. Zhang Wei, President of the China Drug Supervision and Administration Research Association, attended and delivered a speech, while Su Shengfeng, a member of the Party Leadership Group of the Guangdong Provincial Drug Administration, gave a keynote report. Relevant regulatory departments at all levels in Guangdong Province, leaders from review and certification associations, relevant pharmaceutical industry associations, and representatives from several enterprises attended the event.
Zhang Wei stated that this meeting focused on the hot and difficult issues in drug regulatory policies, laws, and technologies, discussing together and building consensus, which is quite rare. He mentioned that with the official issuance of the "Healthy China 2030" planning outline, promoting the modernization of the drug regulatory system and capacity building, facilitating the high-quality development of the pharmaceutical industry, and accelerating China's transition from a major pharmaceutical country to a strong pharmaceutical country is not only a major strategic deployment made by the country but also a goal for the pharmaceutical industry to strive for in the new development stage. In the face of the growing health needs of the people, how to stimulate the innovative vitality of pharmaceutical companies through institutional reform, promote the research and development of more new drugs, and further improve the accessibility of medications for the public has become a focus of concern for all sectors of society.
Su Shengfeng delivered a report titled "Committed to Reform, Building a Dual Zone - Specific Practices of Comprehensive Drug Supervision Reform in Guangdong Province." He stated that the high-quality development of the industry cannot be separated from the new pattern of social governance of co-construction, co-governance, and sharing. The Provincial Drug Administration, after in-depth analysis and careful consideration, proposed a strategic thinking and work goal of "holding high the banner of comprehensive drug supervision reform and striving to create a national drug quality safety demonstration zone and a national drug industry high-quality development demonstration zone" based on the actual situation in Guangdong. Specific work includes issuing the "Guangdong Province Drug Safety Responsibility Assessment Plan," establishing a national vaccine regulatory system evaluation and vaccine regulatory quality management system, formulating and issuing the "Provincial Bureau Drug Comprehensive Reform Project Management Measures," implementing the "Key Project, Key Enterprise, Key Area Innovation Service Management Measures (Trial)," and launching the "Guangdong-Hong Kong-Macao Greater Bay Area Drug Medical Device Regulatory Innovation Development Work Plan" and the "Guangdong Province Implementation Plan for Promoting High-Quality Development of the Cosmetics Industry," as well as formulating the "Implementation Plan for the Professionalization and Specialization of Drug Inspectors" and a series of supporting systems, actively promoting the evaluation of the national vaccine regulatory system, etc.
The Guangdong Provincial Food and Drug Review Certification Technology Association reported on the work for the 2020-2021 period to the representatives present. The association adheres to the concept of meticulously refining every precise service for the industry and enterprises, focusing on professional services in review and certification, and promoting high-quality industrial development. In this meeting, it proposed the development positioning of "cultivating core competitiveness and collaboratively promoting high-quality industrial development."
The meeting also invited representatives from outstanding member units of the association, such as Guangzhou Baiyi Shenzhou Biopharmaceutical Co., Ltd., China National Pharmaceutical Group Guangzhou Co., Ltd., Sun Yat-sen University Da'an Gene Co., Ltd., Perfect (China) Co., Ltd., and Guangdong Anyuan Cosmetics Technology Co., Ltd., to share insights and experiences on high-quality industrial development.
At the meeting, the second Spring and Autumn Quality Management Improvement Series was announced, including outstanding quality managers, outstanding regulatory affairs managers, and outstanding quality improvement projects, to encourage the emergence of more quality management and regulatory affairs management elites in the pharmaceutical industry, enhance the overall risk control level of the industry, and promote quality upgrade and innovative development.
It is reported that from the 9th to the 10th, there were also activities such as the Guangdong-Hong Kong-Macao Biopharmaceutical and Biopharmaceutical Engineering Intellectual Property Forum, Cosmetics Summit, Health Food Summit, Drug Summit, and Medical Device Summit.